These researchers developed a Markov macrosimulation model using life-tables and morbidity data from a national burden of disease study, in order to evaluate cost-effectiveness of a H. pylori serologybased screening programme in New Zealand in 2011 compared with current medical practice. The cost of the screening programme was estimated at NZ$24,600 per quality-adjusted life year (QALY) gained for the total population. The targeted screening program for Māori was more cost effective at $11,985 per QALY gained. Compared to current practice, the total net cost of a one-off total population H. pylori screening programme for the 25–69-year age group was $293 million, with estimated health gains of 14,200 QALYs over the cohort’s lifetime, corresponding to a 17% reduction in the expected future gastric cancer cases and deaths.